To Compare Therapeutic Effect of Intravitreal Bevacizumab and Triamcinolone in Resistant Uveitic Cystoid Macular Edema
Information source: Shahid Beheshti Medical University
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Resistant Cystoid Macular Edema
Intervention: Intravitreal injection of Triamcinolone (Drug); Intravitreal injection of Avastin (Drug)
Phase: Phase 1
Status: Active, not recruiting
Sponsored by: Shahid Beheshti Medical University Official(s) and/or principal investigator(s): Masoud Soheilian, MD, Principal Investigator, Affiliation: Ophthalmic Research Center of Shaheed Beheshti Medical University
Summary
Cystoid macular edema (CME) is one of the common causes of vision loss in patients with
UveitiS .Triamcinolone has been effectively used in reducing CME and improving the vision.
Also there are some documents which recommend Bevacizumab(avastin) could reduce macular
edema. This study compare intravitreous injection of triamcinolone and avastin in patients
with resistant uveitic cystoid macular edema.
Clinical Details
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Primary outcome: Resorbed CME in OCTResorbed CME in clinical examination
Secondary outcome: need to retreatment
Detailed description:
This study compare intravitreous injection of triamcinolone and avastin in patients with
resistant uveitic cystoid macular edema.
Eligibility
Minimum age: N/A.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Uveitic CME
- Uveitic CME refractory to routine treatment
- Vision better than 5/200 and worse than 20/50
Exclusion Criteria:
- Mono- Ocular patients
- History of vitrectomy
- Glaucoma or ocular hypertension
- History of other retinal disease that can cause macular edema
- Pregnancy
- Significant media opacity
- Vision better than 20/50
Locations and Contacts
Masoud Soheilian , MD, Tehran 16666, Iran, Islamic Republic of
Additional Information
Starting date: August 2006
Last updated: July 28, 2008
|